Superluminal Medicines: Funding, Investors & Team (Oct 2026)
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a combination of biology, chemistry, machine learning, and big data analysis. By using advanced computational and machine-learning techniques, they are able to identify and optimize potential drug candidates more quickly and efficiently than traditional methods. Their approach combines experimental data with algorithms to expedite the discovery of therapeutic compounds.
Superluminal Medicines has raised $185M across 3 funding rounds on record, the most recent a Series B of $65.5M announced in Sep 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Superluminal Medicines Company Profile and Key Stats
Latest funding round on record: Sep 2026.
Superluminal Medicines Funding Rounds
1 of 3 rounds was announced without a disclosed amount and is excluded from the total.
Superluminal Medicines raised $120M in a Series A announced in Sep 2024.
11 months later, an undisclosed round was announced in Aug 2025 with no disclosed amount.
1.1 years later, a Series B of $65.5M was announced in Sep 2026.
Superluminal Medicines Investors
12 investors are recorded in total; the 5 named above are those the record identifies.
Superluminal Medicines Founders and Leadership Team
Contact details for the Superluminal Medicines team: 2 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Superluminal Medicines Funding Compared to Other Biotechnology Startups
Superluminal Medicines' latest round of $65.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Superluminal Medicines in Biotechnology and Boston
Companies Similar to Superluminal Medicines
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Superluminal Medicines Funding FAQs
What does Superluminal Medicines do?
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a combination of biology, chemistry, machine learning, and big data analysis. By using advanced computational and machine-learning techniques, they are able to identify and optimize potential drug candidates more quickly and efficiently than traditional methods. Their approach combines experimental data with algorithms to expedite the discovery of therapeutic compounds.
How much funding has Superluminal Medicines raised?
Superluminal Medicines has raised $185M across 3 rounds on record. The most recent is a Series B of $65.5M announced in Sep 2026.
When did Superluminal Medicines last raise funding?
Superluminal Medicines' most recent funding round on record is a Series B of $65.5M, announced in Sep 2026.
Who has invested in Superluminal Medicines?
Investors on record for Superluminal Medicines include RA Capital Management, NVIDIA, Insight Partners, Gaingels, Eli Lilly. FundedIQ records 12 investors in total.
Who founded Superluminal Medicines?
FundedIQ lists Ajay Yekkirala (Co-founder & Chief Scientific Officer), Cony D'cruz (Founder) at Superluminal Medicines.
Where is Superluminal Medicines headquartered?
Superluminal Medicines is based in Boston, Massachusetts, United States.
How many employees does Superluminal Medicines have?
Superluminal Medicines is in the 11-50 employee band.
When was Superluminal Medicines founded?
Superluminal Medicines was founded in 2022.
How does Superluminal Medicines' funding compare to other Biotechnology startups?
Superluminal Medicines' latest round of $65.5M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Superluminal Medicines Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Superluminal Medicines is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.